SCHEMBL2302479

SCHEMBL2302479

Cc1c(Oc2ccccc2)[c]c(Oc2ccccc2)cc1C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RIPK1 Q13546 1/20 0.32
RAF1 P04049 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2306847 0.80 LTA4H (0.38) LTA4HTSHRALDH1A1
SCHEMBL2303320 0.79 TTR (0.37) LTA4HTSHRALDH1A1RIPK1
SCHEMBL2304879 0.73 LTA4H (0.41) LTA4HTSHRALDH1A1RIPK1
SCHEMBL2302914 0.70 LTA4H (0.46) LTA4HTSHRALDH1A1
SCHEMBL2304755 0.69 ALDH1A1 (0.36) TSHRALDH1A1
SCHEMBL2465788 0.69 LTA4H (0.41) LTA4HTSHR
SCHEMBL10323072 0.68 LTA4H (0.39) LTA4HTSHRALDH1A1RIPK1
SCHEMBL18274774 0.68 LTA4H (0.41) LTA4HTSHRALDH1A1RIPK1
SCHEMBL5632254 0.67 LTA4H (0.38) LTA4HTSHRALDH1A1RIPK1
SCHEMBL2302460 0.67 KDM4E (0.43) LTA4HTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023190912-A1 POLAR-GROUP-CONTAINING OLEFIN COPOLYMER AND METHOD FOR PRODUCING SAME 日本ポリケム株式会社 2023-10-05 WO disclosed
EP-3978537-B1 POLAR GROUP-CONTAINING OLEFIN COPOLYMER UNIV TOKYO (JP) 2023-09-13 EP disclosed
US-20220220239-A1 POLAR GROUP-CONTAINING OLEFIN COPOLYMER THE UNIVERSITY OF TOKYO (JP) 2022-07-14 US disclosed
WO-2020241715-A1 POLAR GROUP-CONTAINING OLEFIN COPOLYMER 国立大学法人東京大学 2020-12-03 WO disclosed
US-20160237184-A1 IMINE COMPOUND, NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER JAPAN POLYPROPYLENE CORPORATION (JP) 2016-08-18 US disclosed
EP-3050892-A1 IMINE COMPOUND AND NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND METHOD FOR PRODUCING OLEFIN POLYMER Japan Polypropylene Corporation (JP) 2016-08-03 EP disclosed
EP-2351761-B1 NOVEL METAL COMPLEX, AND METHOD FOR PRODUCING -OLEFIN POLYMER AND METHOD FOR PRODUCING -OLEFIN/(METH)ACRYLATE COPOLYMER EACH USING THE METAL COMPLEX JAPAN POLYPROPYLENE CORP (JP) 2015-12-02 EP disclosed
US-8618319-B2 Metal complex and method for producing α-olefin polymer and method for producing α-olefin/(meth)acrylate copolymer using the same JAPAN POLYPROPYLENE CORPORATION (JP) 2013-12-31 US disclosed
US-20110213110-A1 NOVEL METAL COMPLEX AND METHOD FOR PRODUCING ALPHA-OLEFIN POLYMER AND METHOD FOR PRODUCING ALPHA-OLEFIN/(METH)ACRYLATE COPOLYMER USING THE SAME JAPAN POLYPROPYLENE CORPORATION (JP) 2011-09-01 US disclosed
EP-2351761-A1 NOVEL METAL COMPLEX, AND METHOD FOR PRODUCING -OLEFIN POLYMER AND METHOD FOR PRODUCING -OLEFIN/(METH)ACRYLATE COPOLYMER EACH USING THE METAL COMPLEX Japan Polypropylene Corporation (JP) 2011-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237184-A1 IMINE COMPOUND, NOVEL CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER ODC1, MACF1, MOGAT2 LTA4H 2434/4885TSHR 4532/4885ALDH1A1 1043/4885
US-20110213110-A1 NOVEL METAL COMPLEX AND METHOD FOR PRODUCING ALPHA-OLEFIN POLYMER AND METHOD FOR PRODUCING ALPHA-OLEFIN/(METH)ACRYLATE COPOLYMER USING THE SAME OPRD1, OSTC, COG7 LTA4H 2152/4885TSHR 4090/4885ALDH1A1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.